Evidence map›Paper›PMID 33236895›Full record

ArticleBiochemistry2020

Biochemical Validation of a Fourth Guanidine Riboswitch Class in Bacteria.

Hubert Salvail, Aparaajita Balaji, Diane Yu, Adam Roth, Ronald R Breaker

Abstract read
In one paragraph

Article in Biochemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed.

  1. Deciphering guanidine assimilation and riboswitch-based gene regulation in cyanobacteria for synthetic biology applications.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  2. Article
  3. Article
  4. Review
  5. Biomolecular NMR assignments · 2025
    Article
  6. Article
  7. The current riboswitch landscape inMicrobiology (Reading, England) · 2024
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Crystal structure of a GCN5-related N-acetyltransferase from Lactobacillus curiae.Acta crystallographica. Section F, Structural biology communications · 2023
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Canavanine utilizationRSC chemical biology · 2022
    Article
  19. Review
  20. Discovery of a NiNature · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hubert SalvailDepartment of Molecular, Cellular and Developmental Biology, Yale University, New Haven, Connecticut 06520-8103, United States.
Aparaajita BalajiDepartment of Molecular, Cellular and Developmental Biology, Yale University, New Haven, Connecticut 06520-8103, United States.
Diane YuDepartment of Molecular, Cellular and Developmental Biology, Yale University, New Haven, Connecticut 06520-8103, United States.
Adam RothHoward Hughes Medical Institute, Yale University, New Haven, Connecticut 06520-8103, United States.
Ronald R BreakerDepartment of Molecular, Cellular and Developmental Biology, Yale University, New Haven, Connecticut 06520-8103, United States.ORCID 0000-0002-2165-536X

Funding

X-RAY ANALYSIS OF PROTEIN STRUCTURE AND FUNCTIONP01GM022778 · NIGMS · YALE UNIVERSITY · PI BREAKER, RONALD R · 1985 to 2019
$26.1M
Predoc Training at the Interface Chemistry and BiologyT32GM067543 · NIGMS · YALE UNIVERSITY · PI CRAWFORD, JASON MICHAEL · 2003 to 2022
$7.4M
Exploiting Riboswitch Sensors to Reveal Antibiotics Uptake and Retention in Gram Negative BacteriaR01AI136794 · NIAID · YALE UNIVERSITY · PI BREAKER, RONALD R, KAZMIERCZAK, BARBARA I · 2018 to 2022
$5.6M
Discovery and Characterization of New RiboswitchesR01GM136969 · NIGMS · YALE UNIVERSITY · PI STROBEL, SCOTT A · 2020 to 2023
$1.6M
Howard Hughes Medical InstituteNIAID NIH HHS R01 AI136794NIGMS NIH HHS P01 GM022778NIGMS NIH HHS R01 GM136969NIGMS NIH HHS T32 GM067543
6 · The paper itself

Abstract

An intriguing consequence of ongoing riboswitch discovery efforts is the occasional identification of metabolic or toxicity response pathways for unusual ligands. Recently, we reported the experimental validation of three distinct bacterial riboswitch classes that regulate gene expression in response to the selective binding of a guanidinium ion. These riboswitch classes, called guanidine-I, -II, and -III, regulate numerous genes whose protein products include previously misannotated guanidine exporters and enzymes that degrade guanidine via an initial carboxylation reaction. Guanidine is now recognized as the primal substrate of many multidrug efflux pumps that are important for bacterial resistance to certain antibiotics. Guanidine carboxylase enzymes had long been annotated as urea carboxylase enzymes but are now understood to participate in guanidine degradation. Herein, we report the existence of a fourth riboswitch class for this ligand, called guanidine-IV. Members of this class use a novel aptamer to selectively bind guanidine and use an unusual expression platform arrangement that is predicted to activate gene expression when ligand is present. The wide distribution of this abundant riboswitch class, coupled with the striking diversity of other guanidine-sensing RNAs, demonstrates that many bacterial species maintain sophisticated sensory and genetic mechanisms to avoid guanidine toxicity. This finding further highlights the mystery regarding the natural source of this nitrogen-rich chemical moiety.

Indexed as

RiboswitchAptamers, NucleotideGene Expression Regulation, BacterialGuanidineLigandsModels, MolecularNucleic Acid ConformationNucleotide MotifsRNA, BacterialAptamers, NucleotideGuanidineLigandsRiboswitchRNA, Bacterial

Identifiers

PMID33236895
PMCPMC7919255

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.